Canada Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By State - Forecasts From 2025 To 2030

  • Published : Jun 2025
  • Report Code : KSI061617505
  • Pages : 82
excel pdf power-point

Canada Pain Management Drugs Market Size:

The Canadian pain management drugs market is expected to grow at a CAGR of 3.19% from 2025 to 2030.

The rising prevalence of chronic diseases is one of the major drivers of the pain management drugs market in the country. In this regard, obesity is regarded as one of the significant factors that is fueling the growth of the market in Canada.

A World Obesity Federation report forecasts that over 10 million Canadians will be overweight or obese by 2025. The report approximates that the cost of caring for obesity-related disease across the world will amount to $1.5 trillion each year starting in 2025, when 2.7 billion people (one-third of the population of the planet) will be overweight or obese individuals. In Canada, 34% of individuals above 18 years of age will be living with obesity in eight years.  Obesity worsens joint strain, with every additional pound producing 4–6 pounds of pressure on knees and resulting in a higher prevalence of arthritis in obese persons vs in individuals with average BMI.

The rise in the prevalence of skin care conditions, especially chronic afflictions like psoriasis and eczema, is another primary growth driver of Canada's pain management market. Around 1 million people have psoriasis , and 17% have eczema, both frequently associated with neuropathic or inflammatory pain.  The conditions, fueled by environmental and stress factors, drive the need for pain relief products, such as topical analgesics and non-opioid drugs. The sophisticated treatments, like biologics and phototherapy, though dealing with skin manifestations, occasionally demand concomitant pain control, driving the market higher.

Furthermore, cosmetic treatments such as laser and chemical peel, which have become increasingly popular, may induce post-procedure pain, also fueling the need for pain management devices and drugs.

The ageing population, which is more susceptible to skin pain, and increased awareness of non-opioid alternatives during the opioid crisis, further drive market growth. Restraint in access to dermatological specialist care in rural regions demands greater dependence on pain management solutions, thereby supporting the market's strong growth path.

Canada Pain Management Drug Market Segmentation

  • By Drug Type
    • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
    • Corticosteroids
    • Acetaminophen
    • Opioid
      • Strong Opioid
      • Weak Opioid
    • Antidepressants
    • Anticonvulsant Drugs
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Indication
    • Cancer
    • Rheumatoid Arthritis
    • Chronic Back Pain
    • Post-Operative Pain
    • Others
  • By State
    • Ontario
    • Quebec
    • British Columbia
    • Alberta
    • Manitoba

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. CANADA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. CANADA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. CANADA PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. CANADA PAIN MANAGEMENT DRUGS MARKET BY STATE

8.1. Introduction

8.2. Ontario

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Quebec

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. British Columbia

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Alberta

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Manitoba

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Merck & Co., Inc.

10.2. Johnson & Johnson

10.3. Apotex Inc.

10.4. Bausch Health Companies Inc.

10.5. Phyxable

10.6. Novartis Pharmaceuticals Corporation (Novartis AG)

10.7. Eli Lilly and Company

10.8. Pfizer Inc.

10.9. Abbott Laboratories

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

LIST OF FIGURES

LIST OF TABLES

Merck & Co., Inc.

Johnson & Johnson

Apotex Inc.

Bausch Health Companies Inc.

Phyxable

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

Abbott Laboratories